Table 1.

Information about participants with Parkinson’s disease.

Participant	Sex	Age	Time post-diagnosis	Medications	Monotonicity	Speech rate	Reduced loudness	Overall severity
WPD1	F	72,6	1	Mirapex	2.83	2.67	2.67	2.72
WPD2	F	69, 9	9	Eldepryl	1.33	1.33	2.00	1.55
WPD3	F	50, 11	2	Comtan, Sinemet	1.33	1.00	1.00	1.11
WPD4	F	74, 4	5	Bromocriptine, Eldepryl, Sinemet	2.00	1.83	1.00	1.61
WPD5	F	79, 9	6	Eldepryl, Requip, Stalevo	1.33	1.83	1.00	1.39
WPD6	F	75, 4	4–5	Carbidopa-Levodopa	1.67	1.33	2.67	1.89
WPD7	F	75, 11	1	None	2.67	3.00	1.67	2.45
WPD8	F	68, 9	3	Comtan, Mirapex, Sinemet	3.00	1.67	2.00	2.22
MPD1	M	83, 5	5	None	6.33	5.33	6.50	6.05
MPD2	M	76, 5	5	Comtan, Requip, Sinemet	5.67	5.67	4.33	5.22
MPD3	M	68, 10	3–4	Permax, Stalevo	3.00	1.33	2.00	2.11
MPD4	M	90, 2	3	Amantadine, Carbidopa	4.67	1.67	2.00	2.78
MPD5	M	74, 7	3	Carbidopa, Comtan, Permax	3.00	2.67	3.67	3.11
MPD6	M	72, 9	9	Sinemet	3.83	3.00	1.33	2.72
MPD7	M	70, 0	4	Sinemet	3.50	3.50	1.67	2.89
MPD8	M	82, 0	4	Amantadine, Sinemet	2.33	1.33	3.33	2.33

Age is in years, months. Time post-diagnosis is in years. Rating scale: 1.00–1.99 = normal, 2.00–3.99 = mild, 4.00–5.99 = moderate, and 6.00–7.00 = severe.